Meprelon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meprelon

What is Meprelon? Defining the Medicine's Core Identity

Meprelon is a prescription medication containing the active substance Methylprednisolone. It is classified as a powerful synthetic glucocorticosteroid used for its profound anti-inflammatory and immunosuppressive effects throughout the body.

Property Description
Active ingredient Methylprednisolone
Pharmacological class Systemic Glucocorticosteroid
Forms available Tablet, and powder/solvent for injection/infusion
General purpose Reducing severe inflammation and modulating the immune system
Origin Synthetic (analog of natural cortisol)

Meprelon: Identity and Pharmacological Classification

Meprelon belongs to the Systemic Glucocorticosteroid class, a category of steroid hormones structurally related to the body's natural stress hormone, cortisol. The active ingredient, Methylprednisolone, is a synthetic compound that is clinically recognized for its high potency and intermediate duration of action, differentiating it from shorter-acting agents. Methylprednisolone is regarded as an essential medicine due to its importance as a systemic anti-inflammatory and immunosuppressive agent. This classification indicates the medicine is highly valued for its ability to swiftly control inflammatory processes.

Active Components and Therapeutic Forms

Meprelon is a single-ingredient product. The active component, Methylprednisolone, is often formulated as various esters to optimize its absorption and speed of action. It is primarily available as oral tablets and as a powder and solvent for preparing a solution for injection or infusion. The availability of the injection form is a key differentiator, allowing for intravenous administration—a critical need in emergency settings for immediate systemic absorption. Methylprednisolone functions in its various forms by preventing the release of substances in the body that cause inflammation.

General Purpose and Core Therapeutic Benefit

Because of its potent anti-inflammatory and immunosuppressive properties, the general purpose of Meprelon is to provide rapid and profound relief by modulating the body’s immune responses and reducing severe systemic inflammation. It is frequently used, for example, to suppress acute flare-ups of autoimmune disorders. By profoundly acting upon these processes, Meprelon helps stabilize patients and prevent further tissue damage caused by uncontrolled or destructive bodily reactions.

Regulatory References

  1. World Health Organization (WHO) | About WHO
  2. About the National Library of Medicine
  3. Methylprednisolone: MedlinePlus Drug Information

What side effects are possible with Meprelon?

Possible Side Effects and Safety Information

The safety profile of Meprelon (Methylprednisolone) details adverse reactions across multiple body systems, as documented in government regulatory sources. These effects are classified by their documented frequency.

Documented Adverse Reactions

Side effects are often categorized by the system or organ they affect, spanning metabolic, musculoskeletal, gastrointestinal, and neuro-psychiatric classes. The frequency of these effects varies:

Frequency Classification Examples of Documented Effects
Very Common Increased risk of infection.
Common Increased appetite, hypertension, sodium and fluid retention, peptic ulceration.
Frequency Not Known Adrenal suppression, Cushingoid state, osteoporosis, growth retardation in children, muscle weakness, glaucoma, and posterior subcapsular cataract.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for serious adverse reactions, which include acute myocardiopathy (reported with pulse therapy), tendon rupture, and severe psychiatric reactions.

Safety notes for specific populations are also included:

  • Pediatric Population: Risk of growth retardation is a documented adverse effect.
  • Older Adults: This group may face an increased risk of severity for common adverse reactions like osteoporosis and hypertension.

Furthermore, effects like adrenal suppression are officially noted as being associated with long-term exposure and higher administered doses. Meprelon is contraindicated in individuals with systemic fungal infections or a known hypersensitivity to the active substance.

Overdose and Emergency Response

The official regulatory profile for Meprelon overdose distinguishes between acute exposure and prolonged, high-dose use. While acute overdosage is generally not expected to produce life-threatening symptoms, severe and life-threatening events, including cardiac arrest, arrhythmias, and circulatory collapse, are documented specifically in the context of rapid, high-dose intravenous bolus administration of the injectable form.

Manifestations of chronic overdosage reflect excessive systemic glucocorticoid activity, which may include psychic derangements (such as insomnia, mood swings, or psychotic features), hypertension, salt and water retention, and the development of a Cushingoid state. Children on prolonged high-dose therapy are also noted to be at risk for suppression of growth.

Scenario Regulator-Mandated Action
Suspected Overdose Seek immediate medical attention.
Life-Threatening Symptoms Call emergency services (911) or the Poison Control center if collapse, seizure, or trouble breathing occurs.

No specific antidote is known for methylprednisolone. The primary management strategy defined in regulatory labeling is symptomatic and supportive therapy. Due to the documented cardiac risks, the use of high-dose intravenous administration requires specific safety constraints, including the availability of ECG monitoring and a defibrillator in the treatment setting.

Therapeutic Uses of Meprelon

Main Uses of Meprelon

Meprelon contains methylprednisolone, a synthetic glucocorticoid used to treat a wide range of inflammatory, allergic, and autoimmune conditions. It works by mimicking the effects of hormones naturally produced by the adrenal glands to suppress immune system activity and reduce swelling.

Inflammatory and Rheumatic Disorders

Meprelon is frequently used to manage acute episodes or long-term symptoms of rheumatic diseases. It helps reduce joint pain, stiffness, and inflammation in conditions such as:

  • Rheumatoid arthritis and juvenile idiopathic arthritis.
  • Psoriatic arthritis and ankylosing spondylitis.
  • Acute gouty arthritis.
  • Bursitis and synovitis.

Allergic Reactions

The medication is effective in controlling severe or disabling allergic conditions that do not respond to conventional treatments. These include:

  • Bronchial asthma.
  • Contact and atopic dermatitis.
  • Seasonal or perennial allergic rhinitis.
  • Serum sickness and drug hypersensitivity reactions.

Autoimmune and Systemic Diseases

Meprelon is used during flare-ups of systemic diseases where the immune system attacks the body's own tissues, such as:

  • Systemic lupus erythematosus (SLE).
  • Systemic dermatomyositis (polymyositis).
  • Acute rheumatic carditis.

Dermatological Conditions

Certain severe skin diseases are managed with Meprelon to reduce extensive inflammation and blistering, including:

  • Pemphigus.
  • Stevens-Johnson syndrome (bullous erythema multiforme).
  • Exfoliative dermatitis.
  • Severe psoriasis.

Other Medical Applications

Because of its broad immunosuppressive properties, Meprelon is also utilized in various other clinical areas:

  • Ophthalmic diseases: To treat severe acute and chronic allergic and inflammatory processes involving the eye.
  • Respiratory diseases: Such as symptomatic sarcoidosis or fulminating pulmonary tuberculosis (when used alongside appropriate antituberculosis chemotherapy).
  • Hematological disorders: Including certain types of anemia and a reduction in platelet counts (thrombocytopenia).
  • Gastrointestinal diseases: To help patients through critical periods of ulcerative colitis and Crohn's disease.
  • Oncology: As palliative management for certain leukemias and lymphomas.

Eligibility and Restrictions for Use

Meprelon's eligibility profile is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use populations. Adults are the standard use population.

Absolute Contraindications

Use is prohibited in patients with systemic fungal infections or known hypersensitivity to methylprednisolone or any product constituent. Patients receiving immunosuppressive doses must not receive live or live, attenuated vaccines. Additionally, specific injectable formulations containing Benzyl Alcohol are contraindicated for use in premature infants and neonates.

Conditional and Restricted Use

The medicine requires caution in patients with:

  • Hepatic impairment (cirrhosis) or hypothyroidism (due to enhanced drug effect).
  • Conditions like systemic sclerosis or recent myocardial infarction.
  • Active tuberculosis (must be used concurrently with an appropriate anti-tuberculous regimen).

Age and Physiological Restrictions

While use in the pediatric population is established, children require routine growth monitoring. Older adults should be treated with caution, requiring close clinical supervision. Use during pregnancy necessitates a careful assessment of benefits versus potential fetal risks; infants should be observed for hypoadrenalism. Use while breastfeeding requires a benefit-risk analysis, as the drug is excreted in small amounts in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Meprelon (Methylprednisolone) based on regulatory information. The interactions are classified by how they affect drug exposure or compound pharmacodynamic risks.

Contraindicated Combinations

Co-administration with live or live, attenuated vaccines is contraindicated when Meprelon is administered at immunosuppressive doses. Furthermore, specific drug combinations, such as Desmopressin, are also listed as contraindicated due to the enhanced risk of hyponatremia.

Pharmacokinetic and Exposure Modification

Meprelon is a substrate of the metabolic enzyme CYP3A4. Co-administration with CYP3A4 inhibitors (e.g., antifungals) decreases clearance, leading to increased plasma concentrations and potential for enhanced effects. Conversely, CYP3A4 inducers (e.g., Rifampicin, Carbamazepine) increase clearance, resulting in decreased plasma concentrations and potential reduction in efficacy. Estrogen derivatives can also increase the blood levels of Meprelon.

Pharmacodynamic Risk Enhancement

Interactions that compound clinical risks include combining Meprelon with NSAIDs, which increases the risk of gastrointestinal hemorrhage. Co-administration with Fluoroquinolone antibiotics is documented to potentiate the risk of tendon rupture. The official profile also notes the need for close monitoring with Oral Anticoagulants (e.g., Warfarin), as the effect on coagulation is variable. Meprelon effects are also enhanced in patients with underlying Hypothyroidism or Cirrhosis.

Mechanism of Action

Meprelon (methylprednisolone) is a synthetic glucocorticoid receptor (GR) agonist.

Upon passive diffusion across the cell membrane, Meprelon binds to the intracellular GR in the cytoplasm, forming a ligand-receptor complex. This complex then translocates to the cell nucleus. Within the nucleus, the complex acts through two primary molecular pathways: transactivation and transrepression.

In transactivation, the complex binds to Glucocorticoid Response Elements (GREs) on the DNA, upregulating the transcription of anti-inflammatory genes, such as those encoding lipocortin-1 (Annexin A1). Lipocortin-1, in turn, inhibits the enzyme phospholipase A2.

In transrepression, the complex inhibits the activity of pro-inflammatory transcription factors, including Nuclear Factor-kappa B (NF- kB) and Activator Protein-1 (AP-1), suppressing the transcription of pro-inflammatory mediators. This downstream cascade results in decreased synthesis of prostaglandins, leukotrienes, cytokines (e.g., IL-1, IL-6, TNF-alpha), and chemokines.

System-level physiological consequences include the stabilization of lysosomal membranes, reduced capillary permeability, and suppression of immune cell migration and function, notably of T-lymphocytes and neutrophils, leading to broad immunosuppressive and anti-inflammatory modulation.

Dosage and Administration Information

How to Use Meprelon

The use of Meprelon (methylprednisolone) is defined by official administration guidelines that dictate the route, schedule, and necessary procedural steps, all of which are subject to individual adjustment.

Administration Scope Detail
Route of Administration The medicine is administered orally (tablets) or parenterally (Intravenous [IV] or Intramuscular [IM] injection/infusion).
Dosing Schedule Dosage is highly individualized based on the specific clinical status and is not fixed. Initial daily doses typically range from 4 mg to 48 mg. For acute, severe episodes, high-dose IV pulse therapy, up to 1,000 mg per day, may be administered for a short, limited course.
Frequency and Tapering The total daily dose may be administered once daily, in divided doses, or on an Alternate-Day Therapy (ADT) schedule, depending on the phase of treatment. Following any prolonged use, the medicine must be gradually withdrawn (tapered) rather than stopped suddenly.
Intake Conditions Oral tablets should be taken with food or milk to help minimize potential gastrointestinal irritation.
Preparation / IV Rate The powder form for injection requires reconstitution. High-dose IV infusion (e.g., 250 mg or greater) must be administered slowly, typically over a minimum of 30 minutes, to ensure proper procedural control.
Missed Dose Rule If a once-daily dose is missed, it should be taken when remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped to maintain the schedule.

Connection to the overall use protocol: These instructions establish a protocol where the administration method is chosen based on the need for rapid systemic delivery (IV/IM vs. Oral), followed by a strict time-based adjustment strategy. This dictates that the starting dose must be individually determined and is subsequently reduced in a controlled tapering process, ensuring the overall administration period adheres to a predetermined schedule and controlled dosage reduction pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Meprelon

Research on Meprelon includes various studies conducted for conditions characterized by systemic inflammation and immune activity. This evidence helps outline the scope of its clinical evaluation in authoritative sources.

Evidence for use in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Research has explored Meprelon's role in managing conditions associated with periods of heightened symptom activity, such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Investigators have conducted Randomized Controlled Trials (RCTs) and observational cohort studies. Studies in RA focused on outcomes related to physical discomfort and objective disease activity scores. Some trials reported patterns related to joint damage outcomes when tracked over long time intervals. In SLE, research has examined its use during episodes where symptoms become more noticeable, monitoring outcomes related to remission induction and organ function. Findings described changes in disease activity scores in patients with acute, severe flares.

Evidence for use in Acute Inflammatory States

Meprelon was studied for use in acute episodes, such as acute asthma exacerbations, across many controlled clinical trials. The outcomes examined were primarily related to episodic changes, such as measuring changes in lung function parameters and tracking hospitalization rates. Findings described patterns observed in studies that reported measurements of change in these outcomes within the first 24 hours of administration. Existing studies provide limited research on long-term patterns related to future symptom recurrence following a single course.

Scientific Gaps and Research Uncertainty

Research on Meprelon highlights key areas of scientific uncertainty. Evidence quality varies across studies, especially between high-certainty RCTs for acute events and lower-certainty observational data used for long-term chronic disease management. Comparative evidence is lacking in some areas, and there is limited information for long-term outcomes tracking the impact of chronic, low-dose exposure across many years.

Key Studies & References Methylprednisolone - StatPearls - Authoritative review of indications and general evidence base (NIH)

Frequently Asked Questions (FAQ)

Common questions about Meprelon (FAQ)


Q: How quickly do the effects of Meprelon usually start?

A: According to official product information, the active substance is rapidly absorbed after being taken by mouth. The highest concentration in the bloodstream is typically reached in about 1.5 to 2.3 hours in healthy adults. When administered by injection, official labeling notes that effects often begin to occur even sooner due to rapid systemic delivery.


Q: How long does Meprelon stay in your system after taking it?

A: Regulatory documents indicate that the average elimination half-life, the time for half the drug to be removed, is generally between 1.8 and 5.2 hours. Because Meprelon is classified as an intermediate-acting agent, its effects are generally understood to last longer than the measured half-life.


Q: What is the difference between Meprelon and other 'olone' drugs like prednisolone?

A: Meprelon is a synthetic glucocorticoid, similar to other 'olone' medications. Official labeling describes its active ingredient, methylprednisolone, as having a higher potency and an intermediate duration of action. The difference is related to its potency classification and intermediate duration of action.


Q: Can Meprelon affect blood sugar levels?

A: Yes, official labeling notes that Meprelon can increase blood sugar levels. For individuals who already have diabetes, this may increase the need for their current diabetic medications. In some cases, use of the medicine has also been documented to cause or reveal previously undiagnosed diabetes (latent diabetes mellitus).


Q: Is Meprelon safe to use if I have high blood pressure?

A: Official information documents that Meprelon can sometimes cause or worsen high blood pressure (hypertension) as a common adverse reaction. If you have pre-existing high blood pressure, medical professionals may monitor your condition closely during treatment, as this is a risk that requires careful assessment by a healthcare provider.


Q: Can people with kidney problems use Meprelon?

A: According to official regulatory drug information, generally, no specific dosage adjustments are necessary in cases of renal (kidney) failure. However, caution is advised when using the medication with any pre-existing kidney condition, and its use requires clinical supervision.


Q: Does Meprelon interact with alcohol consumption?

A: While regulatory documents do not specify a direct drug-alcohol interaction, official warnings suggest that consuming alcohol may increase the risk of certain side effects. This combination may make the stomach more susceptible to irritation and ulcers.


Q: Is it true that Meprelon can cause fluid retention?

A: Yes, official safety information documents that sodium and fluid retention is a possible and common adverse reaction to the medicine. This may be noticeable as swelling, particularly in the hands, ankles, or feet.


Q: Why is Meprelon sometimes prescribed for allergies?

A: Meprelon is a corticosteroid that works by preventing the body from releasing substances that cause inflammation and immune responses. Due to these powerful properties, official uses documented in regulatory sources include the treatment of various inflammatory conditions, including certain severe allergic disorders.


Q: Can Meprelon cause insomnia or sleep issues?

A: Yes, official safety documents list insomnia (trouble sleeping) and general restlessness among the documented side effects. These effects are part of the medicine's documented impact on the nervous system.


Q: Is it common to feel jittery or restless after using Meprelon?

A: The official side effects list includes restlessness and excitement, which are ways users sometimes describe feeling 'jittery.' If experienced, this is considered one of the documented psychiatric reactions to the medication.


Q: What happens if a person misses a dose of Meprelon?

A: The official guidance for a once-daily dose provides specific instructions for when a dose is missed. However, for schedules involving divided doses or alternate-day therapy, a medical professional should be consulted to confirm the protocol.


Q: Does Meprelon have a risk of dependence or addiction?

A: The labeling emphasizes that after long-term use, Meprelon must be gradually withdrawn, or 'tapered,' rather than stopped suddenly. This is because abrupt cessation can lead to physical withdrawal symptoms due to the body becoming physically accustomed to the drug.


Q: Can Meprelon cause weight gain?

A: Yes, weight gain is listed in the official safety information as one of the documented, common side effects of the medicine.


Q: Is Meprelon safe for older adults (seniors)?

A: The use of Meprelon in the elderly population is established. However, official information notes that older adults may have an increased risk of severe adverse reactions, such as hypertension (high blood pressure) and osteoporosis (bone thinning), requiring closer clinical supervision during treatment.


Q: Does Meprelon interact with common herbal supplements?

A: Official information generally advises caution regarding herbal products because there is very little regulatory data on their specific interactions with Meprelon. For this reason, official sources recommend informing a medical professional about all supplements being taken.


Q: Is Meprelon considered a fast-acting or slow-acting medication?

A: The active substance, methylprednisolone, is classified as an intermediate-acting glucocorticoid. Due to its properties, it is frequently used to provide rapid and profound systemic effects, especially when administered via injection for acute issues.


Q: Can Meprelon affect bone density over time?

A: Yes, official safety documents list osteoporosis, which is the thinning of bones, as a documented adverse effect, particularly with long-term use. This loss of bone density may be a significant concern during extended therapy.


Q: Is there a link between Meprelon and stomach upset?

A: Yes, stomach upset, irritation, and nausea/vomiting are documented among the possible side effects. Official instructions recommend taking oral tablets with food or milk to help minimize potential gastrointestinal irritation.


Q: Does Meprelon interact with specific vitamins?

A: Yes, regulatory drug interaction data notes that Meprelon may reduce the effects of Vitamin D3. The co-administration of the two may require increased monitoring or a potential dose adjustment.


Q: Why are dosage amounts for Meprelon so different for various conditions?

A: Official documents emphasize that dosage requirements are highly variable and must be individualized based on the specific disease being treated and the patient's response. Doses can range widely, for instance, from lower maintenance doses required for chronic conditions to very high doses required for severe, acute inflammatory events.


Q: How often is Meprelon typically taken for acute conditions?

A: For acute or severe situations, high doses may be administered intravenously for a short, limited course, sometimes as a single high dose daily (pulse therapy). Oral administration for acute flares is often a short course lasting just a few days.

How should Meprelon be stored and disposed of?

How to Store and Dispose of Meprelon

Storage and disposal requirements for Meprelon (methylprednisolone) are strictly defined by regulatory labeling to maintain potency and ensure safety.


Official Storage Requirements

Requirement Category Official Regulatory Statement
Temperature & Protection Store oral tablets at Controlled Room Temperature (20 C to 25 C) away from excess heat and moisture. Do not freeze the medication.
Container Rules Keep the oral tablets in the original container, which must be kept tightly closed.
Child-Safety All forms must be stored out of the sight and reach of children.
Special Handling The injectable powder requires protection from light during storage.

Disposal Instructions

Unused or expired medication should be safely disposed of using a community drug take-back program. If a program is unavailable, the product may be prepared for household trash by mixing it with an undesirable substance (like coffee grounds or dirt) and placing it in a sealed container. All personal information must be removed from the original container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meprelon found in:

A-Z Index: